期刊
DIGESTIVE DISEASES
卷 34, 期 5, 页码 580-588出版社
KARGER
DOI: 10.1159/000445268
关键词
Nuclear hormone receptor; Transmembrane G protein-coupled receptor; Norursodeoxycholic acid (norUDCA); Obeticholic acid (OCA); Ursodeoxycholic acid (UDCA)
资金
- Falk
- Roche
- Gilead
- Albireo
- Intercept
- MSD
The intracellular nuclear receptor farnesoid X receptor (FXR) and the transmembrane G protein-coupled receptor 5 (TGR5) respond to bile acids (BAs) by activating transcriptional networks and/or signaling cascades. These cascades affect the expression of a great number of target genes relevant for BA, cholesterol, lipid and carbohydrate metabolism, as well as genes involved in inflammation, fibrosis and carcinogenesis. FXR activation in the liver tissue and beyond, such as the gut-liver axis, kidney and adipose tissue, plays a role in metabolic diseases. These BA receptors activators hold promise to become a new class of drugs to be used in the treatment of chronic liver disease, hepatocellular cancer and extrahepatic inflammatory and metabolic diseases. This review discusses the relevant BA receptors, the new drugs that target BA transport and signaling and their possible applications. (C) 2016 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据